Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 12, 2022
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics and Transaction Details
- Principal Amount: $68,750
- Net Proceeds: $65,000 (intended for general working capital)
- Transaction Costs: $3,750 paid to Sixth Street Lending LLC for legal fees and due diligence
- Interest Rate: 8% per annum (payable in cash or shares of common stock)
- Maturity Date: April 12, 2023
- Investor: Sixth Street Lending LLC
Material Changes and Terms
The Company entered into a Securities Purchase Agreement with Sixth Street Lending LLC. Key terms include:
- Conversion Rights: The Note is convertible into common stock at the option of Sixth Street, exercisable 180 days after issuance. The conversion price is set at 65% of the Market Price (a 35% discount), based on the average of the lowest three trading prices over the ten trading days prior to conversion.
- Conversion Cap: Conversion is restricted if it would cause Sixth Street to beneficially own more than 4.99% of outstanding common stock.
- Prepayment Penalties: Prepayment is allowed but subject to escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Provisions: Upon certain events of default, the outstanding principal and accrued interest increase to 150% (the "Default Amount"). Failure to deliver shares upon conversion incurs a penalty of $1,000 per day.
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use the net proceeds for general working capital purposes. The transaction is expected to close on or about April 18, 2022.
Risks and Covenants:
- Asset Disposition: The Company covenants not to sell or dispose of substantially all assets outside the ordinary course of business without consent, which would render it a "shell company."
- Listing Maintenance: An event of default occurs if the Company fails to maintain its listing on OTC markets or major exchanges (Nasdaq, NYSE, AMEX).
- Reporting Compliance: Failure to comply with SEC reporting requirements or restatement of financial statements with a material adverse effect constitutes a default.
- Dilution Risk: The 35% discount on the conversion price and potential issuance of shares for interest payments may result in significant dilution to existing shareholders.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of the $65,000 net proceeds.
- Monitor the Company's ability to maintain its OTC or exchange listing to avoid default triggers.
- Review the Company's cash burn rate to assess the necessity of the working capital and potential need for further financing.
- Track the Company's stock price volatility, as the conversion price is tied to the lowest trading prices, which could accelerate dilution.
- Confirm the Company's compliance with SEC reporting requirements to prevent default events.